{"id":4579,"date":"2025-03-31T18:12:13","date_gmt":"2025-03-31T18:12:13","guid":{"rendered":"https:\/\/kidneydiseaseclinic.net\/kdc\/neostigmine-txt\/"},"modified":"2025-03-31T18:12:13","modified_gmt":"2025-03-31T18:12:13","slug":"neostigmine-txt","status":"publish","type":"post","link":"https:\/\/kidneydiseaseclinic.net\/kdc\/neostigmine-txt\/","title":{"rendered":"neostigmine.txt"},"content":{"rendered":"

CLINICAL USE <\/H3>
\nMyasthenia gravis Antagonist to non-depolarising neuromuscular blockade

DOSE IN NORMAL RENAL FUNCTION <\/H3>Myasthenia gravis: neostigmine bromide 15\u201330 mg at suitable intervals throughout day \u2013 total daily dose 75\u2013300 mg; Neostigmine metilsulfate, IM, SC, 1\u20132.5 mg \u2013 usual total daily dose 5\u201320 mgAntagonist to non-depolarising neuromuscular blockade: 50\u201370 mcg\/kg over 1 minute; maximum dose 5 mg

PHARMACOKINETICS <\/H3>
  • Molecular weight &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp :223.3 (303.2 as bromide); (334.4 as metilsulphate)<\/li>\n
  • %Protein binding &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp :15\u201325<\/li>\n
  • %Excreted unchanged in urine &nbsp &nbsp : 50<\/li>\n

  • Volume of distribution (L\/kg) &nbsp &nbsp &nbsp :0.5\u20131<\/li>\n

  • half-life \u2013 normal\/ESRD (hrs)&nbsp &nbsp &nbsp :0.8\u20131.5\/3

    DOSE IN RENAL IMPAIRMENT <\/H3>

    GFR (mL\/MIN)<\/H4>
  • 20 to 50 &nbsp &nbsp : 50\u2013100% of normal dose
  • 10 to 20 &nbsp &nbsp : 50\u2013100% of normal dose
  • <10 &nbsp &nbsp &nbsp &nbsp &nbsp : 50\u2013100% of normal dose

    DOSE IN PATIENTS UNDERGOING RENAL REPLACEMENT THERAPIES <\/H3>
  • CAPD &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp:Unknown dialysability. Dose as in GFR <10 mL\/min <\/p>\n
  • HD &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp :Unknown dialysability. Dose as in GFR <10 mL\/min
  • HDF\/high flux &nbsp :Unknown dialysability. Dose as in GFR <10 mL\/min
  • CAV\/VVHD &nbsp &nbsp &nbsp:Unknown dialysability. Dose as in GFR 10 to 20 mL\/min

    IMPORTANT DRUG INTERACTIONS <\/H3>Potentially hazardous interactions with other drugsAminoglycosides, clindamycin and polymyxins antagonise effects of neostigmine

    ADMINISTRATION <\/H3>

    Reconstition<\/H4>\u2013

    Route <\/H4>Neostigmine bromide: Oral Neostigmine metilsulfate: SC, IM, IV

    Rate of Administration <\/H4>IV: Very slowly

    Comments<\/H4>\u2013

    OTHER INFORMATION <\/H4>Neostigmine 0.5 mg IV = 1\u20131.5 mg IM\/SC =15 mg orallyWhen used for reversal of non- depolarising neuromuscular blockade, atropine (0.6\u20131.2 mg IV) or glycopyrronium should be given before or with neostigmine in order to prevent bradycardia, excessive salivation and other muscarinic actions of neostigmineThe physicochemical nature of neostigmine may tend to encourage its removal by various renal replacement therapies.
    \n","protected":false},"excerpt":{"rendered":"

    CLINICAL USE Myasthenia gravis Antagonist to non-depolarising neuromuscular blockade DOSE<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1],"tags":[7],"class_list":["post-4579","post","type-post","status-publish","format-standard","hentry","category-blog","tag-post-by-auto-php"],"_links":{"self":[{"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/posts\/4579","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/comments?post=4579"}],"version-history":[{"count":0,"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/posts\/4579\/revisions"}],"wp:attachment":[{"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/media?parent=4579"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/categories?post=4579"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/tags?post=4579"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}